Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/104549
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeArtigo de periódicopt_BR
dc.titleNational Survey About Management And Treatment Options Of Hepatitis C Recurrence After Liver Transplantation [resultado Do Inquérito Nacional Sobre Condutas No Acompanhamento E No Tratamento Da Recurrência Da Hepatite C Em Portadores De Vírus C Submetidos A Transplante De Fígado]pt_BR
dc.contributor.authorBittencourt P.L.pt_BR
dc.contributor.authorDe Silva R.D.C.S.M.A.pt_BR
dc.contributor.authorPessoa M.G.pt_BR
dc.contributor.authorMarroni C.A.pt_BR
dc.contributor.authorAbdalla E.pt_BR
dc.contributor.authorAlmeida M.D.pt_BR
dc.contributor.authorCoelho H.S.pt_BR
dc.contributor.authorCoppini A.Z.pt_BR
dc.contributor.authorCouto C.A.pt_BR
dc.contributor.authorIasi M.pt_BR
dc.contributor.authorLyra A.C.pt_BR
dc.contributor.authorMatos C.pt_BR
dc.contributor.authorMedeiros Filho J.E.pt_BR
dc.contributor.authorParolin M.B.pt_BR
dc.contributor.authorPereira L.M.M.B.pt_BR
dc.contributor.authorReichert P.R.pt_BR
dc.contributor.authorReis M.R.pt_BR
dc.contributor.authorStucchi R.S.B.pt_BR
dc.contributor.authorViana C.F.G.pt_BR
unicamp.authorStucchi, R.S.B., Hospital Das Clínicas, Universidade Estadual de Campinas, SP, Brazilpt_BR
unicamp.author.externalBittencourt, P.L., Hospital Português, Salvador, BA, Brazil, R. P. Clementino Fraga, 220 / 1901, Ondina - 40170-050 - Salvador, BA, Brazilpt
unicamp.author.externalDe Silva, R.D.C.S.M.A., Hospital de Base de São José do Rio Preto, SP, Brazilpt
unicamp.author.externalPessoa, M.G., Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazilpt
unicamp.author.externalMarroni, C.A., Irmandade da Santa Casa de Misericórdia de Porto Alegre, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, SP, Brazilpt
unicamp.author.externalAbdalla, E., Hospital Das Clínicas, Faculdade de Medicina, Universidade de São Paulo, SP, Brazilpt
unicamp.author.externalAlmeida, M.D., Hospital Israelita Albert Einstein, São Paulo, SP, Brazilpt
unicamp.author.externalCoelho, H.S., Universidade Estadual do Rio de Janeiro, RJ, Brazilpt
unicamp.author.externalCoppini, A.Z.pt
unicamp.author.externalCouto, C.A., Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazilpt
unicamp.author.externalIasi, M., Hepato, São Paulo, SP, Brazilpt
unicamp.author.externalLyra, A.C., Hospital San Rafael, Salvador, BA, Brazilpt
unicamp.author.externalMatos, C., Hospital do Câncer, São Paulo, SP, Brazilpt
unicamp.author.externalMedeiros Filho, J.E., UNIMED, João Pessoa, PB, Norwaypt
unicamp.author.externalParolin, M.B., Hospital Das Clínicas, Universidade Federal do Paraná, Curitiba, PR, Brazilpt
unicamp.author.externalPereira, L.M.M.B., Hospital Universitário Osvaldo Cruz, Recife, PE, Brazilpt
unicamp.author.externalReichert, P.R., Hospital São Vicente de Paula, Passo Fundo, RS, Brazilpt
unicamp.author.externalReis, M.R., Hospital Das Clínicas de Porto Alegre, RS, Brazilpt
unicamp.author.externalViana, C.F.G., Centro de Transplante de Fígado, Fortaleza, CE, Brazilpt
dc.description.abstractBackground - Recurrence of hepatitis C after orthotopic liver transplantation is one of the major clinical challenges faced by the liver transplantation community. Treatment of hepatitis C recurrence with peguilated interferon and ribavirin has been associated with sustained virological response in 21% to 45% of treated patients. Furthermore, it has been shown to halt disease progression after orthotopic liver transplantation and to prevent graft failure and the need for retransplantation at least in those subjects with sustained virological response. However, treatment of hepatitis C recurrence after orthotopic liver transplantation in Brazil was not recommended according to ministerial Law number 863. Aims - To assess the management and treatment options of hepatitis C recurrence after orthotopic liver transplantation in different liver transplantation centers in Brazil. Methods - Inquiries were sent to active liver transplantation centers throughout the country. Results - Nineteen centers accepted to participate and answered the questionnaire. Altogether they transplanted around 2,800 subjects, half of them with hepatitis C. Immunosuppressive regimen is comprised by tacrolimus and short-term prednisone in 53% of the centers. One third of them claim to use different schedules for hepatitis C patients. Protocol biopsies for diagnosis of recurrence are employed by 13 centers. Different histological criteria are used for the either diagnosis or decision for treatment in most of the centers. Approximately half of them (42%) indicate treatment in subjects with less severe stages of fibrosis (less than F2 according to METAVIR classification). All centers are referring patients for treatment with peguilated interferon and ribavirin, for 1 year, for 6 months or 1 year based on the genotype, or a la carte based on response, respectively, in 32%, 21% and 47% of the centers. Most of them (84%) do not stop treatment in early non-responders at the 12th week. Conclusions - Even in the absence of national guidelines and federal support, most of the liver transplantation centers in Brazil are treating patients with hepatitis C recurrence after orthotopic liver transplantation.en
dc.relation.ispartofArquivos de Gastroenterologiapt_BR
dc.date.issued2007pt_BR
dc.identifier.citationArquivos De Gastroenterologia. , v. 44, n. 1, p. 78 - 84, 2007.pt_BR
dc.language.isoptpt_BR
dc.description.volume44pt_BR
dc.description.issuenumber1pt_BR
dc.description.firstpage78pt_BR
dc.description.lastpage84pt_BR
dc.rightsabertopt_BR
dc.sourceScopuspt_BR
dc.identifier.issn42803pt_BR
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-34447526582&partnerID=40&md5=0e23e757df350655dbc82d45b14bf85cpt_BR
dc.date.available2015-06-30T18:43:55Z
dc.date.available2015-11-26T14:32:48Z-
dc.date.accessioned2015-06-30T18:43:55Z
dc.date.accessioned2015-11-26T14:32:48Z-
dc.description.provenanceMade available in DSpace on 2015-06-30T18:43:55Z (GMT). No. of bitstreams: 1 2-s2.0-34447526582.pdf: 94257 bytes, checksum: 47efe499b9af3c4f56b8df39fc9de6fb (MD5) Previous issue date: 2007en
dc.description.provenanceMade available in DSpace on 2015-11-26T14:32:48Z (GMT). No. of bitstreams: 2 2-s2.0-34447526582.pdf: 94257 bytes, checksum: 47efe499b9af3c4f56b8df39fc9de6fb (MD5) 2-s2.0-34447526582.pdf.txt: 40499 bytes, checksum: cabe176e976073aec4d5b236eeacf7cd (MD5) Previous issue date: 2007en
dc.identifier.urihttp://www.repositorio.unicamp.br/handle/REPOSIP/104549
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/104549-
dc.identifier.idScopus2-s2.0-34447526582pt_BR
dc.description.referenceAssociação Brasileira de Transplante de Órgãos - ABTO, , http://www.abto.org.brpt_BR
dc.description.referenceBedossa, P., Poynard, T., An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group (1996) Hepatology, 24, pp. 289-293pt_BR
dc.description.referenceBerenguer, M., Ferrell, L., Watson, J., Prieto, M., Kim, M., Rayon, M., Cordoba, J., Wright, T.L., HCV-related fibrosis progression following liver transplantation: Increase in recent years (2000) J Hepatol, 32, pp. 673-684pt_BR
dc.description.referenceBerenguer, M., Prieto, M., Rayon, J.M., Mora, J., Pastor, M., Ortiz, V., Carrasco, D., Berenguer, J., Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation (2000) Hepatology, 32, pp. 852-858pt_BR
dc.description.referenceBerenguer, M., Host and donor risk factors before and after liver transplantation that impact HCV recurrence (2003) Liver Transpl, 9, pp. s44-ss7pt_BR
dc.description.referenceBerenguer, M., Aguilera, V., Prieto, M., San Juan, F., Rayon, J.M., Benlloch, S., Berenguer, J., Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression (2006) J Hepatol, 44, pp. 717-722pt_BR
dc.description.referenceBiggins, S.W., Terrault, N.A., Should HCV-related cirrhosis be a contraindication for retransplantation? (2003) Liver Transpl, 9, pp. 236-238pt_BR
dc.description.referenceBiggins, S.W., Terrault, N.A., Treatment of recurrent hepatitis C after liver transplantation (2005) Clin Liver Dis, 9, pp. 505-523pt_BR
dc.description.referenceBrasil. Portaria n. 863 de 4 de novembro de 2002. Protocolo clínico e diretrizes terapêuticas: hepatite viral crônica C [citado abr 2007] Disponível em: http://saude.ms.dov.br/externo/ downloads/Portaria863HepatitesVirais.docBrillanti, S., Vivarelli, M., De Ruvo, N., Aden, A.A., Camaggi, V., D'Errico, A., Furlini, G., Cavallari, A., Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation (2002) Liver Transpl, 8, pp. 884-888pt_BR
dc.description.referenceDumortier, J., Scoazec, J.Y., Chevallier, P., Boillot, O., Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination (2004) J Hepatol, 40, pp. 669-674pt_BR
dc.description.referenceFeray, C., Caccamo, L., Alexander, G.J., Ducot, B., Gugenheim, J., Casanovas, T., Loinaz, C., Samuel, D., European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group (1999) Gastroenterology, 117, pp. 619-625pt_BR
dc.description.referenceForman, L.M., Lewis, J.D., Berlin, J.A., Feldman, H.I., Lucey, M.R., The association between hepatitis C infection and survival after orthotopic liver transplantation (2002) Gastroenterology, 122, pp. 889-896pt_BR
dc.description.referenceGane, E.J., Portmann, B.C., Naoumov, N.V., Smith, H.M., Underhill, J.A., Donaldson, P.T., Maertens, G., Williams, R., Long-term outcome of hepatitis C infection after liver transplantation (1996) N Engl J Med, 334, pp. 815-820pt_BR
dc.description.referenceGane, E., The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients (2003) Liver Transpl, 9, pp. s28-s34pt_BR
dc.description.referenceLake, J.R., The role of immunosuppression in recurrence of hepatitis C (2003) Liver Transpl, 9, pp. s63-ss6pt_BR
dc.description.referenceMukherjee, S., Gilroy, R.K., McCashland, T.M., Schafer, D.F., Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: A prospective cohort study (2003) Transplant Proc, 35, pp. 1478-1479pt_BR
dc.description.referenceNeff, G.W., Montalbano, M., O'Brien, C.B., Nishida, S., Safdar, K., Bejarano, P.A., Khaled, A.S., Schiff, E.R., Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy (2004) Transplantation, 78, pp. 1303-1307pt_BR
dc.description.referenceNeuberger, J., Treatment of hepatitis C virus infection in the allograft (2003) Liver Transpl, 9, pp. s101-s1s8pt_BR
dc.description.referenceNeumann, U.P., Berg, T., Bahra, M., Puhl, G., Guckelberger, O., Langrehr, J.M., Neuhaus, P., Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up (2004) Transplantation, 77, pp. 226-231pt_BR
dc.description.referenceNeumann, U.P., Berg, T., Bahra, M., Seehofer, D., Langrehr, J.M., Neuhaus, R., Radke, C., Neuhaus, P., Fibrosis progression after liver transplantation in patients with recurrent hepatitis C (2004) J Hepatol, 41, pp. 830-836pt_BR
dc.description.referencePrieto, M., Berenguer, M., Rayon, J.M., Cordoba, J., Arguello, L., Carrasco, D., Garcia-Herola, A., Berenguer, J., High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes (1999) Hepatology, 29, pp. 250-256pt_BR
dc.description.referenceRodriguez-Luna, H., Khatib, A., Sharma, P., De Petris, G., Williams, J.W., Ortiz, J., Hansen, K., Vargas, H.E., Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: An open-label series (2004) Transplantation, 77, pp. 190-194pt_BR
dc.description.referenceRoss, A.S., Bhan, A.K., Pascual, M., Thiim, M., Benedict Cosimi, A., Chung, R.T., Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C (2004) Clin Transplant, 18, pp. 166-173pt_BR
dc.description.referenceSanchez-Fueyo, A., Restrepo, J.C., Quinto, L., Bruguera, M., Grande, L., Sanchez-Tapias, J.M., Rodes, J., Rimola, A., Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft (2002) Transplantation, 73, pp. 56-63pt_BR
dc.description.referenceShiffman, M.L., Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation (2003) Liver Transpl, 9, pp. S14-S20pt_BR
dc.description.referenceSilva, R.C.M.A., Da Silva, R.F., Pessoa, M.G., Sette Jr, H., Couto, C.A., Vilela, E.G., Marroni, C., Bittencourt, P.L., Tratamento da recorrência da hepatite C no pós-operatório do transplante hepático: Resultados de estudo retrospectivo multicêntrico nacional (2005) GED Gastroenterol Endosc Dig, 24, pp. s1pt_BR
dc.description.referenceBrasileira de Hepatologia, S., (2005) Consenso sobre Condutas nas hepatites virais B e C, , http://www.sbhepatologia.org.br/artigos, São Paulopt_BR
dc.description.referenceagosto, Disponível empt_BR
dc.description.referenceWiesner, R.H., Sorrell, M., Villamil, F., Liver Transpl (2003) Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C, pp. 9-s9,1. , spt_BR
dc.description.referenceWright, T.L., How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration? (2003) Liver Transpl, 9, pp. s109-ss13pt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-34447526582.pdf92.05 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.